Pluristem Pops on Cell Therapy Data (PSTI)
Shares of Pluristem Therapeutics Inc. (NASDAQ: PSTI) are popping higher today on word that its cell therapy data shows that its treatments are “Safe” and that its PLX cells may be effective therapy for neuropathic pain.
Shares are trading higher by 3.51%, at $1.18, but hit a high of $1.40 in the pre-market.
The data also shows that placenta-driven cell therapy “improves quality of life.” The company said that is PLX therapy also “meets other efficacy measurements.”
The stock has been rallying as of late and has the possibility to make a major move higher if it can break above $1.28.
Pluristem Therapeutics Inc. is a bio-therapeutics company engaged in developing and intending to commercialize, cell therapy production technologies and products. The company focuses on commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several degenerative, ischemic and autoimmune disorders. It is developing a pipeline of products, stored ready to use, which are derived from human placenta, a non-controversial, non-embryonic adult stromal cell source.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.